Egenesis Stock

egenesisbio.comHealthcare / BioTech & PharmaFounded: 2015Funding to Date: $264.59MM

eGenesis’s goal is to transform the field of transplantation by offering safe and effective organs, tissues, and cells to patients in need by harnessing cutting-edge gene editing technologies to address the key issues that have impeded xenotransplantation to date.

Register To Buy and Sell Shares

For more details on financing and valuation for Egenesis, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Egenesis’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Egenesis.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Frequently Asked Questions About Egenesis’ Stock

Can you buy Egenesis’ stock?
Egenesis is not publicly traded on NYSE or NASDAQ in the U.S. To buy Egenesis’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Egenesis’ stock?
Yes, you can sell stock of a private company like Egenesis. Forge can help you sell your Egenesis stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Egenesis’ stock price?
Egenesis is a privately held company and therefore does not have a public stock price. However, you may access Egenesis’ private market stock price with Forge Data.
What is Egenesis’ stock ticker symbol?
Egenesis does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

The Startup Behind The First Pig-Human Kidney Transplant Is Targeting Hearts And Livers Next
A gene-edited kidney was transplanted into a patient with eGenesis's technology.
eGenesis Announces World’s First Successful Transplant of Genetically Engineered Porcine Kidney in a Living Patient
A pig kidney was transplanted into an adult male by eGenesis.
eGenesis Presents Preclinical Data Demonstrating Recipient Survival and Compatibility with Genetically Engineered Porcine Kidneys at 2023 IPITA-IXA-CTRMS Joint Conference
eGenesis, a biotechnology company, has presented preclinical data on genetically engineered porcine kidneys demonstrating recipient survival and compatibility. The data was presented at the 2023 IPITA-IXA-CTRMS Joint Conference. The company is aiming to develop human-compatible organs for organ transplant, addressing the shortage of organs available for transplant.
Updated on: May 17, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.